Switching to single-use bioreactors can have financial and performance benefits.
Yves Ghislain
Advertisement
Yves Ghislain is an expert scientist at Viral Industrial Bulk, GSK Biologicals
Articles by Yves Ghislain
Advertisement
Latest Updated Articles
Disposable Bioreactors for Viral Vaccine Production: Challenges and OpportunitiesPublished: November 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
